Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Beats Revenue Estimates

Company Performance - Arcutis Biotherapeutics reported a quarterly loss of $0.13 per share, better than the Zacks Consensus Estimate of a loss of $0.18, and an improvement from a loss of $0.42 per share a year ago, representing an earnings surprise of +27.78% [1] - The company posted revenues of $81.5 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 12.32%, compared to year-ago revenues of $30.86 million [2] - Over the last four quarters, Arcutis has exceeded consensus EPS estimates four times and topped consensus revenue estimates four times as well [2] Stock Outlook - The immediate price movement of Arcutis Biotherapeutics shares, which have increased about 10% since the beginning of the year, will depend on management's commentary during the earnings call [3] - The current consensus EPS estimate for the upcoming quarter is -$0.13 on revenues of $82.92 million, and for the current fiscal year, it is -$0.55 on revenues of $312.81 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Arcutis belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Arcutis's stock performance [5]